Skip to main content
. 2019 Sep 27;98(39):e17384. doi: 10.1097/MD.0000000000017384

Figure 2.

Figure 2

Random-effects model of HR (95% CI) of overall survival associated with the irinotecan group compared with the oxaliplatin group. There are no striking heterogeneity in overall survival was found (P = .005, I2 = 59.0%) in the studies. A random-effects model was applied to the meta-analysis. No significant differences were observed in the overall survival between the 2 arms (P = .53). CI = confidence interval, df = degrees of freedom, HR = hazard ratio.